NCT02256709View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

August 31, 2004

Conditions
Healthy
Interventions
DRUG

BIBP 5371 CL tablet

single rising daily doses

DRUG

BIBP 5371 CL solution

OTHER

High fat, high caloric breakfast

DRUG

Placebo tablet

DRUG

BIBP 5371 CL tablet high dose

DRUG

Placebo drinking solution

DRUG

BIBP 5371 CL tablet low dose

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02256709 - Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter